

[a002]

Convenient Synthesis of novel amino acid coupled benzanilides

S. M. El Rayes¹, Ibrahim A. I. Ali¹ and Walid Fathalla*²

¹*Department of Chemistry, Faculty of Science, Suez Canal University, Ismailia, Egypt*

²*Department of Mathematical and Physical Sciences, Faculty of Engineering, Suez Canal University, Port Said, Egypt, email. walid399@yahoo.com*

Summary:

A facile and convenient synthesis of a variety of Methyl 2-(2-Benzoylamino-benzoylamino) alkanoate **4a-d** has been developed by the DCC coupling of 2-Benzoylamino-benzoic acid with amino acid methyl ester. Compounds **4a-c** were alternatively prepared by the reaction of amino acid ester with 3,1-benzoxazinone **2** in pyridine. Dipeptides **8a-j** were subsequently prepared following the azide coupling method. Compounds **4** and **8** were expected to possess antimicrobial activity.

Key Words: antibiotics, TCS, amino acids and dipeptide, DCC and azide coupling, benzanilides, 3,1-benzoxazinone.

Introduction


Pathogenic bacterial resistance to all existing classes of antibiotics has been recently detected. New classes of antibacterial are needed to overcome drug-resistant bacteria following a new mechanism of action. The new generation antibiotics are compounds that inhibit the two-component system (TCS) and are expected to block transcription of several genes in the bacteria. [1]. substituted salicylanilides are well known for their antimicrobial [2] and antifungal [2,3] action. Recently, salicylanilides have showed antimycobacterial activity against classical mycobacterium tuberculosis H37Rv [4]. They were proved to inhibit the bacterial TCS, which is also found in mycobacteria [5, 6]. Imramovský prepared a series of amino acids esters with highly active salicylanilides as a new group of prodrugs with high activity, improved solubility and low toxicity [7].

N-substituted carboxamide series of the isothiazole derivatives produced a remarkable activity: 5-benzoylamino-*N*-(4-ethoxyphenyl)-3-methyl-4-isothiazolecarboxamide (ITF) **I** exhibited significant anti-inflammatory and broad antiviral activity [8], while 5-benzoylamino-*N*-(4-chlorophenyl)-3-methyl-4-isothiazole-carboxamide **II**, i. e. denotivir (ITCL, vratizolin) [9] exhibited antiviral drug, anti-inflammatory and immunotropic activities

The pharmacophoric structure of all these compounds involve the presence of two phenyl rings linked to a spacer unit and two hydrogen bond donor sites. The spacer unit, when present, can be represented by a heterocyclic ring structure **I** and **II**, or by an acyclic moiety structure **III** and other salicylanilide derivatives.


This paper describes our development of a novel series of benzanilide derivatives **IV** whose chemical modifications include *N*-terminal coupled amino acid and dipeptide derivatives to 2-Benzoylamino-benzoic acid as active antibiotics agents. The amidic NH

could also represent one of the required H-bond-donor sites, while the other is the NH group of the amino acid residue.




Results and Discussion:

During the course of our continued interest in the development of new general synthetic routes for the synthesis of biologically active amino acid coupled derivatives we decided to synthesize methyl 2-(2-Benzoylamino-benzoylamino) alkananoate **4a-d**. Treatment of 2-phenyl-4H-benzo[d][1,3]oxazin-4-one (**2**) with amino acid ester.HCl **3** in pyridine at 120° C for 24 h gave the acyclic amino acid ester derivative **4a-c** in low yield [10]. However, a change in the reaction conditions (more reaction time at elevated temperature) and in the workup procedure (evaporation of pyridine under reduced pressure rather than aqueous workup) did not improve the yield of this reaction. This low yield could be explained by the reversibility of the reaction induced by the oxygen attack at the peptide bond with elimination of amino acid. This was confirmed by an endless amount of benzoxazine isolated from the reaction mixture.



Scheme 1

The structure of acyclic amino acid ester **4a-d** was chemically confirmed by an equivocal synthesis from the acid derivative **1** *via* DCC coupling method with an improvement in the yield of the reaction. The DCC coupling is one of the major tools employed in literature to introduce peptide bonds by the reaction of acid with amino acid methyl ester. hydroxybenzotriazole (HOBT) is widely used as an additive to decrease racemization in the carbodiimide peptide coupling [11-13]. Thus, treatment of acid **1** with the amino acid esters hydrochloride **3** in presence of coupling reagents DCC and HOBT at 0 - 25 °C in acetonitrile afforded amino acid ester **4a-d**, in 40-52 % yield. Benzoxazinone **2** was also isolated from the reaction mixture as a by product, which passively affected the yield of the reaction. This method has the advantage of a multi-component reaction with an overall moderate to good yield from easily available acid derivative **1** at low temperature to minimize the degree of racemization in amino acid coupling. The alternative reaction of benzoxazine in pyridine requires higher temperature and longer reaction time (120 °C, 24 h) to produce **4a-c**. Both reactions reported herein are useful, due to their operational simplicity. In addition, the starting materials are readily available. One of our approaches involves formation of quinazoline **5** *via* intramolecular cyclocondensation of **4a-d**. This approach usually involves similar conditions as employed for pyridine method [10]. However we failed to isolate quinazoline **5** using a variety of conditions (acetic anhydride, AcONa fused 90°C 24 h., DMF NEt₃, NaOMe, MeOH, 60 °C , over night). The synthesis of the target dipeptide derivatives **8a-j** were efficiently formed from key intermediate ester **4a-c** *via* the azide coupling method [12, 13], which was reported to minimize the degree of racemization in amino acid coupling. The synthesis of dipeptide **8a-j** *via* azide-coupling method is shown in Schemes 1, 2. The ester **4a-c** was boiled with hydrazine hydrate in methyl alcohol to afford the hydrazide **6**. The hydrazide **6** was subsequently converted into azide **7** by treatment with NaNO₂ and HCl mixture Scheme 1, 2. The *in situ* generated azide **7** solution in ethyl acetate reacted with amino acid methyl ester hydrochloride **3** in the presence of triethyl amine to afford the the dipeptide derivative **8a-j** in good yield, scheme 2.



scheme 2

The structure assignment of the amino acid ester **4a-d**, hydrazide **6** and dipeptide **8** is based on spectral and physicochemical analysis, Figure 1.




Figure 1. Selected ¹H NMR of compounds **4**, **6** and **8**

All isolated products exhibited a rather interesting conformation as represented in fig 1 and indicated from all ^1H NMR spectra. Thus, the ^1H NMR spectrum of **4a** showed an interesting exchangeable singlet signal at δ 12.0 ppm corresponding to one NH group. This implies that the NH group participate in an intramolecular hydrogen bond interaction of the type $\text{N}-\text{H}\cdots\text{O}=\text{C}$ [9]. Further more, ^1H NMR spectrum exhibited an aromatic proton at δ 8.84 ppm attributed to proton H3 of the phenyl ring, which implies an anisotropy caused by the adjacent carbonyl group. Both the hydrogen bond interaction and this anisotropy are present in all isolated products which indicate the fixed conformation of the basic acyclic skeleton. The ^1H NMR spectrum of **4a** also exhibits three signals at δ 6.85, 4.26 and 3.82 ppm corresponding to NH, CH_2 and OCH_3 of the glycine residue.

References

1. Hlasta, D. J., Demers, J. P., Foletto, B. D., Fraga-Spano, S., Guan, J., Hilligard, J. *J. Bioorg. Med. Chem. Lett.* **1998**, *8*, 1923.
2. Vinšová, J., Imramovský, A. *Ces. Slov. Farm.* **2004**, *53*, 294.
3. Mukta, J., ; Shweta, G., Diwedi, S. C., Joshi, S. C., Singh, R. V., Bansal, A. *Phosphorus, Sulfur, and Silicon and the Related Elements* **2004**, *179*, 1517.
4. Waisser, K., Matyk, J., Divišová, H., Husáková, P., Kuneš, J., Klimešová, V., Kaustová, J., Möllmann, U., Dahse, H., Miko M. *Arch. Pharm. Chem. Life Sci.* **2006**, *339*, 616.
5. Macielag, M. J., Demers, J. P., Fraga-Spano, S. A., Hlasta, D. J., Johnson, S. G., Kanojia, I. M. *J. Med. Chem.* **1998**, *41*, 2939.
6. Waisser, K., Bureš, O., Holý, P., Kuneš, J., Oswald, R., Jirásková, L. *Arch. Pharm. (Weinheim)* **2003**, *336*, 53.
7. Imramovsky, A., Vinsova, J., Ferriz, J. M., Kuneš, J., Pour, M., Dolezal, M., *Tetrahedron Lett.* **2006**, *47*, 5007.
8. Machoń, Z., Wieczorek, Z., Zimecki, M. *Pol. J. Pharmacol.* **2001**, *53*, 377.
9. Regiec, A., Machoń, Z., Mieczybrodzki, R., Szymaniec, S. *Arch. Pharm. Chem. Life Sci.* **2006**, *339*, 401.
10. Desai, A. R., Desai, K. R. *Arkivoc* **2005**, *xiii*, 98.
11. Sahin, G., Palaska, E., Ekizoglu, M., Ozalp, M., *Farmaco* **2002**, *57*, 539.
12. Fathalla, W., Ali, A. I., *Heteroatom Chemistry*, **2007**, *18* (6), in press
13. Ali, I. A. I. Al-Masoudi, I. A., Saeed, B., Al-Masoudi, N. A., La Colla, P., *Heteroatom Chem* **2005**, *16*, 148.
14. Pandey, V. K. *J. Indian Chem. Soc.* **1977**, *LIV*, 1084.

